• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.

作者信息

Tampaki Ekaterini Christina, Tampakis Athanasios, Droeser Raoul, Patsouris Efstratios, Kouraklis Gregory

机构信息

a B Department of Propaedeutic Surgery , Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens , Greece.

b National Organization for the Provision of Healthcare Services, Department of Planning and Monitoring of Medicines Dispensing , Medicines Division , Greece.

出版信息

Cancer Biol Ther. 2018;19(10):847-849. doi: 10.1080/15384047.2018.1433495. Epub 2018 Aug 17.

DOI:10.1080/15384047.2018.1433495
PMID:29442576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6300348/
Abstract
摘要

相似文献

1
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.卡博替尼和凡德他尼治疗甲状腺髓样癌：线粒体功能及其作为设计抗癌症干细胞药物新策略的治疗靶点的潜力
Cancer Biol Ther. 2018;19(10):847-849. doi: 10.1080/15384047.2018.1433495. Epub 2018 Aug 17.
2
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.凡德他尼和卡博替尼增强靶向线粒体的药物以抑制甲状腺髓样癌细胞。
Cancer Biol Ther. 2017 Jul 3;18(7):473-483. doi: 10.1080/15384047.2017.1323594. Epub 2017 May 5.
3
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.卡博替尼和凡德他尼治疗不可切除的局部晚期或转移性甲状腺髓样癌：系统评价和经济模型。
Health Technol Assess. 2019 Feb;23(8):1-144. doi: 10.3310/hta23080.
4
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.卡博替尼和凡德他尼治疗晚期甲状腺髓样癌的真实世界疗效和安全性。
Thyroid. 2021 Mar;31(3):459-469. doi: 10.1089/thy.2020.0206. Epub 2020 Sep 23.
5
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.凡德他尼与卡博替尼治疗甲状腺髓样癌：斑马鱼模型中的抗血管生成作用研究。
Int J Mol Sci. 2021 Mar 16;22(6):3031. doi: 10.3390/ijms22063031.
6
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.卡博替尼（COMETRIQ⁰）。在甲状腺髓样癌中：与凡德他尼一样，弊大于利。
Prescrire Int. 2016 Jan;25(167):11-3.
7
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.帕唑帕尼、卡博替尼和凡德他尼在进展性甲状腺髓样癌治疗中的应用，特别关注对高血压的不良反应。
Int J Mol Sci. 2018 Oct 20;19(10):3258. doi: 10.3390/ijms19103258.
8
Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.酪氨酸激酶抑制剂凡德他尼、乐伐替尼和卡博替尼在体外可调节细胞色素P450催化的抗癌药物玫瑰树碱的氧化作用。
Neuro Endocrinol Lett. 2019 Feb;39(7):515-524.
9
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.联合使用辐射和酪氨酸激酶抑制剂可提高甲状腺髓样癌的治疗效果。
PLoS One. 2020 May 27;15(5):e0233720. doi: 10.1371/journal.pone.0233720. eCollection 2020.
10
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.甲状腺髓样癌：临床特征和针对酪氨酸激酶的治疗策略新见解。
Mol Diagn Ther. 2017 Dec;21(6):607-620. doi: 10.1007/s40291-017-0289-5.

引用本文的文献

1
A Synthetic Small RNA Homologous to the D-Loop Transcript of mtDNA Enhances Mitochondrial Bioenergetics.一种与线粒体DNA D环转录本同源的合成小RNA增强线粒体生物能量学。
Front Physiol. 2022 Apr 6;13:772313. doi: 10.3389/fphys.2022.772313. eCollection 2022.
2
ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report.ERBB1和ERBB2阳性的甲状腺髓样癌：病例报告
Diseases. 2018 Apr 10;6(2):25. doi: 10.3390/diseases6020025.

本文引用的文献

1
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.凡德他尼和卡博替尼增强靶向线粒体的药物以抑制甲状腺髓样癌细胞。
Cancer Biol Ther. 2017 Jul 3;18(7):473-483. doi: 10.1080/15384047.2017.1323594. Epub 2017 May 5.
2
Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy.线粒体介导的癌症干细胞对化疗和放疗耐药的绕过机制
Oxid Med Cell Longev. 2016;2016:1716341. doi: 10.1155/2016/1716341. Epub 2015 Nov 30.
3
Management of advanced medullary thyroid cancer.晚期甲状腺髓样癌的治疗管理。
Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71. doi: 10.1016/S2213-8587(15)00337-X. Epub 2015 Oct 23.
4
EMT, CTCs and CSCs in tumor relapse and drug-resistance.肿瘤复发和耐药中的上皮-间质转化、循环肿瘤细胞和癌症干细胞
Oncotarget. 2015 May 10;6(13):10697-711. doi: 10.18632/oncotarget.4037.
5
The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?癌症干细胞微环境：微环境在调节肿瘤细胞干性方面有多重要？
Cell Stem Cell. 2015 Mar 5;16(3):225-38. doi: 10.1016/j.stem.2015.02.015.
6
Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.代谢重编程调控鼻咽癌中的癌症干细胞特性。
Cell Cycle. 2015;14(1):86-98. doi: 10.4161/15384101.2014.974419.
7
Cabozantinib in progressive medullary thyroid cancer.卡博替尼治疗进展性甲状腺髓样癌。
J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.
8
Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy.过氧化物酶体疾病 X 连锁肾上腺脑白质营养不良中线粒体氧化磷酸化受损。
Hum Mol Genet. 2013 Aug 15;22(16):3296-305. doi: 10.1093/hmg/ddt186. Epub 2013 Apr 20.
9
Mitochondria in cancer stem cells: a target for therapy.癌症干细胞中的线粒体：一个治疗靶点。
Recent Pat Endocr Metab Immune Drug Discov. 2013 May;7(2):102-14. doi: 10.2174/18722148113079990006.
10
Ageing, oxidative stress and cancer: paradigms in parallax.衰老、氧化应激与癌症：视差中的范式
Nat Rev Cancer. 2008 Nov;8(11):875-9. doi: 10.1038/nrc2522.